FDA cites Glenmark plant where warehouse temperatures exceeded 110˚F

A recently released FDA Form 483 noted a number of problems it discovered at a Glenmark plant in India.

One of Glenmark’s Indian plants received more than 20 complaints in the last two years about a cream that buyers said was watery. Warehouse records showed that during storage, the drug was exposed for more than 30 hours to temperatures that ran as high as 112˚F, but the company didn’t investigate to see if that might have been the cause.

That is one of the observations among seven laid out in the inspection of the finished formulations plant in Baddi that the company says accounts for about 10% of its U.S. sales. The FDA last week released a highly redacted version of the Form 483 that came out of the five-day visit in November of the facility which makes creams and ointments as well as tablets.  

RELATED: India’s Glenmark reports 7 FDA observations at Baddi facility

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

Temperature excursions were only one of the issues the FDA documented tied to the warehouse at the Baddi plant. Inspectors also noted that warehouse employees had unrestricted access to computers that allowed them to delete records without the QA unit being aware.

In another concern, inspectors found partially destroyed quality records in a shredder that had not been logged for destruction, suggesting a problem the FDA has noted at the plants of other drugmakers.

In a public filing, Glenmark reported the observations and said it was providing a comprehensive response and would reply to the FDA shortly.

Suggested Articles

Novavax will shell out $167 million for Czech manufacturer Praha Vaccines in a move to boost production of a COVID-19 vaccine past 1 billion doses.

The FDA knocked Altaire Pharmaceuticals for falsified data and harebrained contraptions at its New York plant in a scathing warning letter.

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.